WHO-GMP ACCREDITATION FOR PARABOLIC CEPHALOSPORIN FACILITY The Company’s dedicated Cephalosporin API manufacturing Site at Derabassi has been accredited with the WHO-GMP certificate by the Central Drugs Standards Control Organization, DGHS, Ministry of Health & Family Welfare. The Derabassi Campus, housing six manufacturing Plants, two Solvant Recovery Plants, a dedicated Quality Control and Quality Assurance unit,…
→ Read morePARABOLIC ACCREDITED WITH ISO 14001 CERTIFICATION The Company’s Derabassi manufacturing Site has been accredited with the ISO 14001:2004 certificate for meeting the Environmental Management System Standards. This 27 acre facility, a dedicated Cephalosporin API & intermediate manufacturing site, was audited by DNV (Det Norske Veritas) certification agency from Netherlands and found to be compliant…
→ Read moreBTS India Private Equity Fund Limited, a Mauritius based Company registered with the Securities and Exchange Board of India (SEBI) as Foreign Venture Capital Investor has invested around USD 7 million in the Company by way of private placement of shares.
→ Read morePDL received Certificate of suitability from the office of European Directorate for the Quality of Medicines & HealthCare, France Monday July16,2007 The Director of European Directorate for the Quality of Medicines & HealthCare has issued certificate of suitability no.RO-CEP 2005-064-Rev 00 to the Company for its product-Flucloxacillin Sodium.
→ Read morePDL commission’s state of the art facilities for the manufacture of Betalactum & Cephalosporins Steriles.
→ Read moreParabolic Drugs Limited has been granted permission to its Panchkula Facility for the supplies to US markets
→ Read moreParabolic Drugs Limited allotted 4,00,000 Optionally Convertible Cumulative Preference shares of the face value of Rs. 100/- each to Minivet Limited a Mauritius based Foreign Institution Investors on private placement of shares of the Company.
→ Read moreParabolic Drugs Limited has started construction of its dosage facility at Baddi in Himachal Pradesh. The facility proposes to manufacture both capsules and injectibles for semi synthetic penicillin’s and cephalosporin’s. The dosage facility is a forward integration for PDL and places PDL in a strategic position since PDL is already a low cost API manufacturer…
→ Read moreRanbaxy has been informed by USFDA that they can now start sourcing 6 APA from Parabolic’s Panchkula facility for Ranbaxy’s US markets. This approval came subsequent to PDL filing a DMF for USFDA approval in 2005 for its Panchkula 6 APA facility. This places PDL in a strategic position in the Pencillins business and also…
→ Read moreParabolic Drugs Limited is planning to offer 25,00,000 shares to the public in its maiden public offer expected in April/May 2006. In this regard the company filed a draft prospectus with SEBI on February 27, 2006. The funds from the issue will be used to fund the expansion plans of PDL which include setting up…
→ Read more